Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $12

Benzinga · 03/12 14:09
Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $8 to $12.